Cumberland Pharmaceuticals (CPIX) Research Hub

Cumberland Pharmaceuticals (CPIX) trades on NASDAQ, US in the Healthcare (Drug Manufacturers - Specialty & Generic) sector. As of 2026-09-11, shares last closed at 6.39 USD (+1.59%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -14.39, market cap 0.11B. This hub links to the full technical, earnings and options research available for CPIX.

Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ

SectorHealthcare (Drug Manufacturers - Specialty & Generic)
ExchangeNASDAQ, US
Last close6.39 USD (+1.59%)
52-week range5.51 USD – 9.28 USD
Trend regimeRange
14-day RSI36 (Bearish)
Trailing P/E-14.39
Market cap0.11B
Dividend yield0.00%

Available research for CPIX

Earnings

CPIX earnings: real EPS beat/miss history, analyst consensus Buy, P/E -14.39. Updated 2026-07-23.

Options: Covered Call

Covered Call on CPIX: how it works, illustrative setup around the real 6.39 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Iron Condor

Iron Condor on CPIX: how it works, illustrative setup around the real 6.39 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Protective Put

Protective Put on CPIX: how it works, illustrative setup around the real 6.39 USD price, max profit/loss, breakeven and when to use it. Educational.

Technical

CPIX technical analysis: range, last 6.39 USD, RSI 36, 52w range 5.51 USD–9.28 USD, real support/resistance. Updated 2026-09-11.

Frequently asked questions

What sector is CPIX in?

Cumberland Pharmaceuticals (CPIX) is classified under Healthcare (Drug Manufacturers - Specialty & Generic), listed on NASDAQ, US.

Is CPIX in an uptrend or downtrend?

As of 2026-09-11, CPIX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.

What is CPIX's trailing P/E ratio?

CPIX's trailing P/E is -14.39, with a market cap of 0.11B. See the earnings research page for full valuation detail.